BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12

• Press Releases

  4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics

  January 8, 2026

   · 

  3 min read
• Press Releases

  PathAI and University Hospital Zurich Announce Collaboration to Deploy AISight® Dx and AIM-TumorCellularity for Routine Molecular Pathology Workflows

  January 8, 2026

   · 

  3 min read
• Press Releases

  Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted Therapeutics in Solid Tumors and Fibrosis

  January 8, 2026

   · 

  2 min read
• Press Releases

  Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference

  January 8, 2026

   · 

  12 min read
• Press Releases

  EnteroBiotix announces positive Phase 2 TrIuMPH results supporting EBX-102-02 as a potential first-in-class, oral, full-spectrum microbiome therapy for irritable bowel syndrome

  January 8, 2026

   · 

  5 min read
• Press Releases

  Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors

  January 8, 2026

   · 

  5 min read
• Press Releases

  Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R Therapeutics

  January 8, 2026

   · 

  3 min read
• Press Releases

  Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy

  January 8, 2026

   · 

  6 min read
• Press Releases

  NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s

  January 8, 2026

   · 

  3 min read
• Press Releases

  Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort

  January 8, 2026

   · 

  4 min read